Citations

Clear

3057 citation(s) found for "Cd, Johnson".

A recurrent ACAA2 variant causes a dominant syndrome of lipodystrophy, lipomatosis, infantile steatohepatitis, and hypoglycemia
Simha, Vinaya , LoPiccolo, Mary Kate , Platt, Anna , Brown, Rebecca J. , Johnson, Xandria, Carere, Deanna Alexis , Donnelly, Colleen , Snyder, Matthew T., Xing, Chao , Mathews, Thomas P. , Gopal, Purva , Tomchick, Diana R. , Agarwal, Anil , Garg, Abhimanyu , Brown, Rebecca J. , Ward, Stephen C. , DeBerardinis, Ralph J. , Xing, Chao

Mayo Clinic

Journal of Clinical Investigation | November 4, 2025 | Volume: 136 | Issue: 1 | Pages: No page available

10.1172/jci198888 | PMID 41186989 Get It

Association between central adiposity and cognitive domain function in recently postmenopausal women: an analysis from the KEEPS-Cog substudy of the Kronos Early Estrogen Preventive Study
James, Taryn T. , Simó, Carola Ferrer, Salazar, Hector , Hulle, Carol A. Van , Wyman, Mary F. , Fischer, Barbara L., Bouges, Shenikqua , Umucu, Emre , Cedars, Marcelle I. , Løbo, Rogerio A. , Neal-Perry, Genevieve, Harman, S. Mitchell , Miller, Virginia M. , Gleason, Carey E. , Dowling, N. Maritza , Simó, Carola A. Ferrer, Ennis, Gilda E. , Johnson, Adrienne L. , McLester‐Davis, Lauren W. Y. , Gooding, Diane Carol , Kara, Firat , Kling, Juliana M. , Manson, JoAnn E. , Brinton, Eliot A. , Santoro, Nanette F. , Naftolin, Frederick , Pal, Lubna , Kantarci, Kejal

Mayo Clinic

Menopause | November 4, 2025 | Volume: 33 | Issue: 2 | Pages: 151-160

10.1097/gme.0000000000002666 | PMID 41186575 Get It

Objective: To determine associations between central adiposity, cognitive function, and randomized menopausal hormone therapy (MHT) in a reanalysis of the Kronos Early Estrogen Prevention Study-Cognitive and Affective (KEEPS-Cog) sub-study participants. Methods: KEEPS randomized 727 women (ages 42-58) who were <36 months postnatural menopause to oral conjugated equine estrogens (o-CEE), transdermal 17-β-estradiol (t-E2), or placebo for 48 months. Participants with diabetes, body mass index >35 kg/m 2 , coronary artery calcium score >50 Agatston Units, and other cardiometabolic disease risk indicators were excluded from enrollment. In the ancillary KEEPS-Cog study, cognitive tests were completed at baseline, 18-, 36-, and 48-month post-randomization. In these analyses, cognitive variables were summarized as four cognitive domain-specific factor scores: verbal learning and memory, auditory attention and working memory, visual attention and executive function, and speeded language and mental flexibility. Waist-hip-ratio (WHR), an indicator of central adiposity, was measured at screening (baseline) and modeled as a covariate in linear latent growth models assessing associations of MHT with cognitive functions at baseline and over time. Results: Higher baseline WHR was associated with poorer performance on all domain-specific cognitive outcomes at baseline and with changes in visual attention and executive function across time. Models including interaction effects were not significant for either o-CEE x WHR or t-E2 x WHR. Conclusion: Central adiposity is a risk factor for domain-specific cognitive decline, and thus, cognitive health effects should be investigated in early postmenopausal women, even in women with low cardiovascular risk statuses.
Threshold-Based Overlap of Breast Cancer High-Risk Classification Using Family History, Polygenic Risk Scores, and Traditional Risk Models in 180,398 Women
Ho, Peh Joo , Loo, Christine Kim Yan , Lim, Ryan Jak Yang, Goh, Mui Heng, Abubakar, Mustapha , Ahearn, Thomas U. , Andrulis, Irene L. , Antonenkova, Natalia, Aronson, Kristan J. , Augustinsson, Annelie , Behrens, Sabine , Bodelón, Clara , Bogdanova, Natalia , Bolla, Manjeet K. , Brantley, Kristen D. , Brenner, Hermann , Byers, Helen L., Camp, Nicola J. , Cessna, Melissa H., Chang-Claude, Jenny, Choi, Ji-Yeob , Czene, Kamila , Dörk, Thilo , Eliassen, A. Heather , Engel, Christoph , Eriksson, Mikael , Evans, D. Gareth , Fritschi, Lin , Genkinger, Jeanine M. , Geurts-Giele, Willemina R.R. , Glendon, Gord, Hall, Per , Hamann, U. , Ho, Cecilia Y.S., Hooning, Maartje J. , Hoppe, Reiner , Humphreys, Keith , Ito, Hidemi , Jakubowska, Anna , Jernström, Helena , John, Esther M. , Johnson, Nichola , Kang, Daehee , Kim, Sung‐Won , Kitahara, Cari M. , Ko, Yon-Dschun, Kraft, Peter, Kwong, Ava , Lambrechts, Diether, Larsson, Susanna C. , Li, Shuai , Lindblom, Annika , Linet, Martha, Lissowska, Jolanta , Lophatananon, Artitaya , MacInnis, Robert J. , Mannermaa, Arto, Manoukian, Siranoush, Margolin, Sara, Matsuo, Keitaro , Michailidou, Kyriaki , Taib, Nur Aishah Mohd , Murphy, Rachel A. , Newman, William G. , Obi, Nadia , Olopade, Olufunmilayo I., Panayiotidis, Mihalis I. , Park, Sue K. , Park‐Simon, Tjoung‐Won , Patel, Alpa V , Peterlongo, Paolo , Plaseska‐Karanfilska, Dijana , Pylkäs, Katri , Rashid, Muhammad Usman , Rodríguez, Juan , Sandler, Dale P. , Sawyer, Elinor J. , Scott, Christopher G. , Shahi, Shamim , Shu, Xiao‐Ou , Shulman, Katerina, Simard, Jacques , Southey, Melissa C., Stone, Jennifer , Taylor, Jack A. , Teo, Soo‐Hwang , Teras, Lauren R. , Vachon, Celine M., Houdt, Maxime Van , Verhoeven, Jelle , Weinberg, Clarice R. , Wolk, Alicja , Yamaji, Taiki , Yip, Cheng Har , Zheng, Wei , Hartman, Mikael , Li, Jingmei , Investigators, on behalf of the ABCTB, Investigators, kConFab, Investigators, MyBrCa, Investigators, SGBCC, Olopade, Olufunmilayo I. , Lambrechts, Diether , Lambrechts, Diether , Hamann, Ute , Hooning, Maartje J. , Bogdanova, Natalia V , Czene, Kamila , Dörk, Thilo , Eliassen, A Heather , Engel, Christoph , Eriksson, Mikael , Evans, D Gareth , Fletcher, Olivia , Fritschi, Lin , Genkinger, Jeanine , Hall, Per N , Ho, Cecilia Y S , Humphreys, Keith , Ito, Hidemi , Jakubowska, Anna , Jernström, Helena , Johnson, Nichola , Kim, Sung-Won , Kitahara, Cari M , Kwong, Ava , Larsson, Susanna C , Li, Shuai , Lindblom, Annika , Lissowska, Jolanta , Lophatananon, Artitaya , Maclnnis, Robert , Matsuo, Keitaro , Michailidou, Kyriaki , Mohd Taib, Nur Aishah , Murphy, Rachel A , Newman, William G , Obi, Nadia , Panayiotidis, Mihalis I , Park, Sue K , Park-Simon, Tjoung-Won , Peterlongo, Paolo , Plaseska-Karanfilska, Dijana , Pylkäs, Katri , Rashid, Muhammad U , Rennert, Gad , Rodriguez, Juan , Sandler, Dale P , Sawyer, Elinor J , Scott, Christopher , Shu, Xiao-Ou , Simard, Jacques , Stone, Jennifer , Taylor, Jack A , Teo, Soo H , Teras, Lauren R , Houdt, Maxime Van , Verhoeven, Jelle , Weinberg, Clarice R , Wolk, Alicja , Zheng, Wei , Hartman, Mikael , Li, Jingmei , Lambrechts, Diether , Behrens, Sabine , John, Esther M , Olopade, Olufunmilayo I , Lambrechts, Diether , Augustinsson, Annelie , Brenner, Hermann , Camp, Nicola J , Brantley, Kristen D , Lim, Ryan Jak Yang, Byers, Helen, Castelao, Jose E. , Chang‐Claude, Jenny , Chanock, Stephen Jacob , Chenevix‐Trench, Georgia , Colonna, Sarah V. , Daly, Mary Beryl , Derouane, Françoise , Fletcher, Olivia , Gago-Domínguez, Manuela , Ho, Weang-Kee , Howell, Anthony , Iwasaki, Motoki , Ko, Yon‐Dschun, Mannermaa, Arto , Manoukian, Siranoush , Margolin, Sara , Milne, Roger L. , Muir, Kenneth , O’Brien, Katie M. , Rennert, Gad , Saloustros, Emmanouil , Southey, Melissa C. , Terry, Mary Beth , Torres, Diana , Investigators, on behalf of the ABCTB, Investigators, kConFab, Investigators, MyBrCa, Investigators, SGBCC

Mayo Clinic

Cancers | November 3, 2025 | Volume: 17 | Issue: 21 | Pages: 3561

10.3390/cancers17213561 | PMID 41228354 Get It

Background: Breast cancer polygenic risk scores (PRS) and traditional risk models (e.g., the Gail model [Gail]) are known to contribute largely independent information, but it is unclear how the overlap varies by ancestry, age, disease type (invasive breast cancer, DCIS), and risk threshold. Methods: In a retrospective case–control study, we evaluated risk prediction performance in 180,398 women (161,849 of European ancestry; 18,549 of Asian ancestry). Odds ratios (ORs) from logistic regression models and the area under the receiver operating characteristic curve (AUC) were estimated. Results: PRS for invasive disease showed a stronger association in younger (<50 years) women (OR = 2.51, AUC = 0.622) than in women ≥ 50 years (OR = 2.06, AUC = 0.653) of European ancestry. PRS performance in Asians was lower (OR range = 1.62–1.64, AUC = 0.551–0.600). Gail performance was modest across groups and poor in younger Asian women (OR = 0.94–0.99, AUC = 0.523–0.533). Age interactions were observed for both PRS (p < 0.001) and Gail (p < 0.001) in Europeans, whereas in Asians, age interaction was observed only for Gail (invasive: p < 0.001; DCIS: p = 0.002). PRS identified more high-risk individuals than Gail in Asian populations, especially ≥50 years, while Gail identified more in Europeans. Overlap between PRS, Gail, and family history was limited at higher thresholds. Calibration analysis, comparing empirical and model-based ROC curves, showed divergence for both PRS and Gail (p < 0.001), which indicates miscalibration. In Europeans, family history and prior biopsies drove Gail discrimination. In younger Asians, age at first live birth was influential. Conclusions: PRS adds value to risk stratification beyond traditional tools, especially in younger women and Asian ancestry populations.
Predicting Remaining Survival of Glioblastoma Patients with Radiomics Analysis Based on 18F-DOPA PET Images
Qian, J. , Hasenauer, Deanna , Breen, William G. , Brown, Paul D. , Hunt, Christopher H. , Jacobson, Mark, Johnson, Derek R. , Kaufmann, Timothy J. , Kemp, Bradley J. , Kizilbash, Sani H. , Lowe, Val J. , Ruff, Michael W. , Sarkaria, Jann N. , Uhm, Joon H. , Zakhary, Mark J. , Seaberg, Maasa , Tseung, Hok Seum Wan Chan, Yan, Elizabeth , Zhang, Yan , Laack, Nadia N. , Brinkmann, Debra H. , Kemp, Brad , Qian, Jing , Jacobson, Mark S, Seaberg, Maasa H , Wan Chan Tseung, Hok Seum, Yan, Elizabeth S, Laack, Nadia N Issa , Kaufmann, Timothy J , Hunt, Christopher H , Sarkaria, Jann N , Johnson, Derek R , Kizilbash, Sani H , Lowe, Val J

Mayo Clinic

Cancers | November 3, 2025 | Volume: 17 | Issue: 21 | Pages: 3560

10.3390/cancers17213560 | PMID 41228352 Get It

Background: Post-treatment prognosis and monitoring are critical for determining the timing of salvage treatment in glioblastoma patients but has been challenging due to difficulties differentiating progression from treatment effects in conventional images. This exploratory study aimed to establish the correlation of radiomics image features from time series of amino acid tracer 18F-DOPA PET images, with outcomes, using machine learning and dimension reduction analysis. Methods: 18F-DOPA PET images were collected for a patient cohort with wild-type IDH and unmethylated MGMT who underwent dose-escalated radiation therapy. Quantitative features were derived from the high uptake region (T/N > 2.0) in pre- and post-radiation therapy follow-up 18F-DOPA PET images. A customized workflow was utilized for pre-selecting predictive features, followed by manifold learning. Machine learning algorithms were employed to establish associations between imaging features and remaining survival (RS), defined as the time between a follow-up scan and date of death. Results: The ML models exhibited 81–83% ROC_AUC in predicting RS evaluated on an independent test dataset. A RS map is proposed for monitoring tumor alterations through serial 18F-DOPA PET scans, demonstrating superior sensitivity and better correlation with survival compared to the RANO criteria. Conclusions: Our study demonstrates that ML models utilizing FU 18F-DOPA PET images have the potential to effectively predict future survival outcomes in patients with glioblastoma treated with dose-escalated radiation therapy. The capability to assess changes in tumor over time through imaging can potentially assist in patient stratification and the selection of salvage treatments, while also aiding in distinguishing treatment effects from genuine tumor progression.
The double-edged sword: artificial intelligence’s promise and perils in anesthesia patient safety
Maloney, Jillian , Johnson, Brooks , Johnson, Brooks W , Harbell, Monica W.

Mayo Clinic

Current Opinion in Anaesthesiology | November 3, 2025 | Volume: 38 | Issue: 6 | Pages: 776-785

10.1097/aco.0000000000001580 | PMID 41182062 Get It

Purpose of review The rapid growth and integration of artificial intelligence in healthcare has the potential to revolutionize all fields of medicine, including anesthesiology. This review summarizes the role of artificial intelligence in anesthesiology, highlighting how it can enhance patient safety, workflow efficiency, and research capabilities, while also examining the potential risks and ethical issues of introducing this new technology. Recent findings Evolving applications in anesthesiology include closed-loop anesthetic delivery, risk stratification, intraoperative monitoring, natural language processing for literature synthesis, and predictive modeling for adverse events. While these tools offer significant promise for improving efficiency and safety, emerging risks, such as algorithmic bias, lack of transparency, hallucinations, and automation complacency – must be carefully addressed. Regulatory frameworks, clinician education, and transparent model development are necessary to ensure responsible integration. Summary Artificial intelligence is poised to transform anesthetic care, but it must be developed and deployed with caution. Clinician oversight, robust validation, and ethical safeguards are essential to ensure artificial intelligence enhances, rather than replaces, clinical judgment. Strategic adoption can improve patient outcomes, reduce preventable harm, and streamline perioperative workflows.
Abstract 4367364: A Multicenter Friedreich Ataxia Registry Identifies Posterior Wall Thickness as a Predictor of Major Adverse Cardiac Events
Dedio, Anna, McSweeney, K., Fournier, Anne , Yoon, Grace , Payne, R. Mark , Cripe, Linda , Patel, Aarti , Johnson, Jonathan N. , Lynch, David T. , Tate, Barbara , Feng, Yixuan , Mercer‐Rosa, Laura , Lin, Kimberly Y. , Niaz, Talha , McCormack, Shana Erin , Tate, Barbara, Feng, Yixuan, Huang, Jing Yang

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4367364 Get It

Background: Cardiac disease is the leading cause of premature mortality in Friedreich Ataxia (FA). However, validated prognostic indicators or early imaging biomarkers that can reliably predict cardiac events are lacking. To address this gap, we created a multicenter FA cardiac registry to characterize disease progression and identify early echocardiographic (echo) predictors of major adverse cardiac events (MACE). Methods: FA subjects from 6 North American centers with at least two echos performed ≥5 years apart were included. Demographics, FA-specific disease characteristics, and MACE (a composite of death, heart failure hospitalization, aborted sudden cardiac death, and/or life-threatening arrhythmia) were abstracted. Digital echo images were re-read at a centralized core lab. Paired T tests were utilized for comparison of the normally distributed first and second echo parameters, and logistic regression models were utilized to evaluate for predictors of MACE. Results: Of 115 subjects, 52 (45%) were female. Mean age at diagnosis was 10 ± 3 years, median GAA1 repeat length (a marker of genetic severity) was 700 (range 66–1200), and median age at first analyzed echo was 12 years (range 4-36). MACE occurred in 35 (30%) of the cohort. Serial echocardiograms demonstrated progressive worsening of multiple cardiac parameters over time, including markers of ventricular thickness and hypertrophy, chamber size, systolic function, and novel markers of atrial and ventricular strain (Table 1). On univariate analysis, several markers of hypertrophy and systolic function from the earliest analyzed echo predicted MACE. However, after adjusting for age of diagnosis, GAA1 repeat length, and collinearity among variables, only posterior wall thickness in diastole (PWTd) remained an independent predictor of MACE (odds ratio 1.8 per mm increase, 95% CI 1.1–3.3, p = 0.028). Conclusions: This multicenter FA registry identifies early posterior wall thickness as a significant and independent predictor of major adverse cardiac events in FA. Each millimeter increase in PWTd on early echo is associated with nearly double the odds of MACE. This commonly acquired parameter is often overlooked and may serve as a powerful early marker of cardiac risk. Further investigation of PWTd as a potential surrogate endpoint for therapeutic trials in FA is warranted.
Abstract 4364521: The Predictive Capabilities of Exhaled Volatile Organic Compounds on Heart Failure Status: A Pilot Study
Vungarala, Soumya , Kerr, Matt, Wentz, Robert J., Ziegler, Briana, Kim, Chul‐Ho , Birch, Owen, Davies, Huw, Chou, Hsuan , Johnson, Bruce D. , Kerr, Matt

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4364521 Get It

Background: Exhaled volatile organic compounds (VOCs) can provide insight into various physiological and metabolic processes. Aim: The purpose of this study was to determine if exhaled VOCs would differ across disease severity in heart failure (HF) patients. Methods: We recruited 62 individuals who were classified as healthy control (CTL), admissions with fluid overload (DHF), NYHA class I-II or NYHA class II-III. Breath samples were collected using the ReCIVA Breath Sampler (Owlstone Medical Ltd) and analyzed using mass spectrometry and gas chromatography. Typical clinical characteristics were documented at the time of exhaled breath collection. Results: Data were obtained on 16 CTL, 21 DHF, 15 NYHA I-II and 10 NYHA II-III (characteristics shown in Table). For the HF groups, DHF, NYHA I-II and NYHA II-III, the %HPEFF were 32, 63 and 63% respectively. Regarding exhaled VOCs, we observed a stepwise increase in VOCs potentially linked to lipid peroxidation or fatty acid metabolism, such as pent-3-en-2-one, 2-pentanone, and 4-heptanone, as disease severity worsened. A similar trend was seen for sulphur containing compounds (methyl propyl sulfide, allyl methyl sulfide and 1(methyl thiol)-1 propene)), potentially providing insight into impaired hepatic or renal clearance in more advanced HF. The level of methyl pyruvate on breath also rose with increasing disease severity, which may reflect altered energy metabolism. Finally, gut microbiome-related VOCs (acetoin, 2,3-butanediol, and butyric anhydride) increased across severity groups, potentially reflecting dysbiosis in advanced disease. Conclusions: In a small pilot study aiming to identify potential exhaled breath biomarkers in HF, we observed significant differences in VOCs across disease severity. These compounds have been linked to lipid peroxidation, energy metabolism, liver and kidney function as well as microbial fermentation and short-chain fatty acid metabolism. Collectively, these data demonstrate the ability of breath omics to potentially stratify disease severity and provide additional biological insights into HF pathophysiology. Larger studies are needed to determine whether a breath biomarker panel could be established to quantify disease severity and predict decompensation risk in HF.
Abstract 4365928: RT-A1: A Novel Dual GC-A and GC-B Peptide Activator that Attenuates Adverse Myocardial Remodeling in Pre-Clinical Heart Failure with Preserved Systolic Function
Armstrong, David , Johnson, Camryn , Livingston, William H. , Zheng, Ye , Moroni, Dante , Agrawal, Vineet , Livingston, William, Burnett, John, Merryman, W. David

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4365928 Get It

Background: Heart failure (HF) is a complex syndrome marked by adverse cardiac remodeling and natriuretic peptide (NP) deficiency, which drives disease progression despite current therapies. NPs exert cardioprotective effects via particulate guanylate cyclase receptors GC-A and GC-B, which generate cGMP. Activation of GC-A by ANP or BNP induces arteriodilation, natriuresis, antihypertrophic effects, and inhibits the renin-angiotensin-aldosterone system, while GC-B activation by CNP mediates antifibrotic, lusitropic, venodilatory, and anti-inflammatory actions. Existing drugs target either GC-A or GC-B, but none target both. We developed RT-A1, a unimolecular peptide activating both GC-A and GC-B, hypothesizing it will attenuate myocardial remodeling in a preclinical model of HF with preserved systolic function. Methods: RT-A1 was engineered by rational drug design. HEK293 cells expressing human GC-A or GC-B, human cardiac myocytes (CMs) and fibroblasts (CFs) were treated with RT-A1 (10-100nM) and cGMP was measured. In vivo, mice underwent mild transverse aortic constriction (TAC) or sham surgery. After 3 weeks, LV hypertrophy (LVH) was confirmed by echo. TAC mice were then randomized to vehicle (Veh) or RT-A1 (50pmol/kg/min) via subcutaneous osmotic pumps for 3 weeks. Endpoints included LV/body weight ratio, myocyte cross-sectional area (CSA), plasma cGMP, and RNA-seq. Data are mean±SEM. P<0.05 was significant. Results: RT-A1 dose-dependently increased cGMP in HEK293 cells expressing GC-A or GC-B, confirming dual activation, and elevated cGMP in human CMs and CFs. TAC induced significant LV wall thickening with preserved systolic function versus sham. After three weeks, RT-A1 normalized LV/body weight (3.14±0.14 vs. 3.82±0.29, P=0.03) and reduced myocyte CSA (348±16 vs. 506±17, P=0.0005) compared to Veh. Plasma cGMP was higher in TAC+RT-A1 versus TAC+Veh (85±8 vs 54±8 pmol/ml, P=0.01), confirming target engagement. RNA-seq showed reduced LV BNP expression and downregulation of hypertrophy, fibrosis, and inflammation pathways with RT-A1 treatment vs. Veh following TAC. Conclusions: RT-A1 is a novel dual GC-A/GC-B peptide activator that elevates plasma cGMP and reduces adverse cardiac remodeling in experimental HF by downregulating hypertrophy, fibrosis, and inflammation pathways. Dual GC-A/GC-B activation via RT-A1 represents a promising anti-remodeling therapeutic strategy for HF with preserved systolic function warranting further study.
Abstract 4367166: A Multicenter Study of Detection of Pulmonary Hypertension Based on Point-of-Care 12- Lead ECG Data
Agarwal, Richa , Wieczorek, Mikolaj A. , Hackett, Sarah, Carlson, Katherine , Klugherz, Paul, Wagner, Tyler , DuBrock, Hilary M. , Johnson, Patrick W. , Frantz, Robert P. , Strom, Jordan B. , Waks, Jonathan W. , Hemnes, Anna R. , Steinberg, Benjamin A. , Pandey, Ambarish , Hackett, Sarah, Alger, Heather M. , Carter, Rickey E. , Wagner, Tyler

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4367166 Get It

Background: Pulmonary hypertension (PH) is a life-threatening disease affecting up to 1% of the global population. Diagnosis can be challenging and is often delayed due to the need for advanced imaging and invasive procedures. The use of artificial intelligence applied to ECGs (ECG-AI) has been shown to detect subtle patterns in voltage-time data and may be a valuable tool for the early detection of PH. Hypothesis and Purpose: To evaluate the performance of a previously trained, ECG-AI algorithm to detect PH (ECG-AI PH) using real-world data (RWD) collected in a multicenter, validation study. A joint primary hypothesis required sensitivity (Sn), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) to exceed the null values of 76%, 70%, 10% and 90%. Study Design and Methods: This retrospective validation study was conducted at 5 geographically diverse U.S. health systems. Adult subjects were eligible for inclusion if they had a 12-lead ECG paired with an echocardiogram (Echo) in which tricuspid regurgitation velocity (TRV) was recorded, following presentation with dyspnea. Patients were classified according to echocardiographic criteria as either PH (PH+, TRV >3.4 m/s) or controls (PH-, TRV ≤2.8 m/s) to simulate the real-world use of ECG-AI, where a positive result could lead to a follow-up Echo. The study database was locked before processing the digital ECGs with ECG-AI PH. Performance was also estimated in a subset of subjects that later had a right heart catheterization using mPAP ≥ 20mmHg as the definition of PH. Results: A total of 14281 subjects (53% female, 63% aged 50+ years) met the inclusion criteria, including 3019 PH+ cases and 11262 PH- controls (Figure). Sn and Sp were 84.0% (95% CI: 82.6%, 85.3%) and 71.7% (95% CI: 70.9%, 72.6%), respectively. The positive and negative predictive values were 18.9% (95% CI: 18.4%, 19.4%) and 98.3% (95% CI: 98.1%, 98.4%), respectively, at 7.3% prevalence. Each endpoint met pre-defined performance criteria. In the subset of 1683 subjects with a follow up RHC, performance remained robust (Sn 85% (1155/1358); Sp 46% (151/325)). Conclusion: While ECG-AI PH was first developed as an investigational tool to detect PH, continued development as software as a medical device for clinical use demonstrated that the algorithm retained strong performance to detect PH in diverse, non-overlapping clinical settings and patient populations.
Prioritization of outcome measures in regional anesthesia research
El‐Boghdadly, Kariem , Ayad, Amany E. , Memtsoudis, Stavros G. , Schreiber, Kristin L. , Radcliffe, Gillian , Rivett, Kate, Princova, Zuzana, Adhikary, Sanjib Das , Candido, Kenneth D., Coppens, Steve , Hanna, Marie N. , Kandil, Enas , Kohan, Lynn , Muse, Iyabo O. , Nsiri, Afak , Pasternak, Jeffrey J., Tolba, Reda, Wolmarans, Morné , Elkassabany, Nabil , Memtsoudis, Stavros G , Schreiber, Kristin L , Adhikary, Sanjib , Albrecht, Eric , Bowness, James , Coppens, Steve , Gupta, Rajnish K , Johnson, Rebecca L , Kohan, Lynn R , Kopp, Sandra , Lobo, Clara , Moka, Eleni , Pino, Carlos A , Singh, Vinita , Van de Putte, Peter B C , Wolmarans, Morné , Elkassabany, Nabil M , El-Boghdadly, K , Narouze, Samer , Myles, Paul S. , Albrecht, Éric , Gupta, Rajnish K. , Johnson, Rebecca L. , Kopp, Sandra L. , Lobo, Clara , Μoka, Εleni , Pino, Carlos A. , Singh, Vinita , Theron, Andre

Mayo Clinic

Regional Anesthesia & Pain Medicine | October 29, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107087

10.1136/rapm-2025-107087 | PMID 41151978 Get It

Background Outcome selection in regional anesthesia and acute pain research is inconsistent, often lacking patient-centered priorities and validated instruments. We aimed to prioritize key outcomes and propose suitable measurement tools to improve the quality, consistency, and relevance of regional anesthesia research. Methods We conducted a multiround Delphi process, including two electronic voting rounds, a multiday in-person meeting, and a patient panel. Experts and patients evaluated existing and proposed outcomes for importance, validity, and relevance. Outcomes reaching ≥70% agreement were prioritized, and appropriate measurement instruments were identified. Results Thirty-two experts and three patients participated. Across three Delphi rounds, 10 outcomes were prioritized for future regional anesthesia research: seven efficacy outcomes (pain scores; opioid consumption; Brief Pain Inventory; functional outcomes; cognitive function; length of stay; block duration); two multidimensional outcomes (quality of recovery and development of a regional anesthesia-specific quality-of-recovery instrument); one safety outcome (chronic postsurgical pain). Patients prioritized cognitive recovery, function, chronic pain, and pain scores. Conclusions This consensus-based, patient-centered framework defines the core priorities for future regional anesthesia and acute pain research. Future work should focus on developing and validating a regional anesthesia-specific quality-of-recovery instrument, refining multidimensional measures such as functional recovery, cognitive outcomes, and the Brief Pain Inventory, and standardizing the reporting of chronic pain and opioid-related outcomes. Adoption of these priorities will enhance methodological consistency, comparability, and patient relevance in future clinical trials.